Combat disorder

disease
On this page

Also known as combat neurosescombat neurosiscombat stress disordercombat stress disordersdisorder, combatdisorder, combat stressdisorders, combatdisorders, combat stressneuroses, combatneuroses, warneurosis, combatneurosis, warshell shockshell Shocksshock, shellShocks, shellstress disorder, combatstress disorders, combatwar neuroses

Summary

Combat disorder (MONDO:0004049) is a disease and 33 clinical trials. Top therapeutic interventions include prazosin hydrochloride, cycloserine, and omega-3-acid ethyl esters. A subtype of acute stress disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 33

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecombat disorder
Mondo IDMONDO:0004049
MeSHD003130
DOIDDOID:6950
SNOMED CT279611005
UMLSC0009426
MedGen40403
Is cancer (heuristic)no

Also known as: combat disorder · combat neuroses · combat neurosis · combat stress disorder · combat stress disorders · disorder, combat · disorder, combat stress · disorders, combat · disorders, combat stress · neuroses, combat · neuroses, war · neurosis, combat · neurosis, war · shell shock · shell Shocks · shock, shell · Shocks, shell · stress disorder, combat · stress disorders, combat · war neuroses (+1 more)

Disease family

This is a subtype of acute stress disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disordermental disorderanxiety disorderacute stress disordercombat disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 33.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified27
PHASE23
PHASE41
PHASE2/PHASE31
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00292370PHASE4COMPLETEDQuetiapine Augmentation for Treatment-resistant PTSD
NCT00475241PHASE2/PHASE3COMPLETEDExposure Therapy for Chronic PTSD: Efficacy and Mechanisms
NCT01216982PHASE2UNKNOWNEffects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders
NCT02266329PHASE1/PHASE2COMPLETEDChronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin
NCT02809326PHASE2COMPLETEDTrauma Management Therapy for OEF and OIF Combat Veterans
NCT04264026PHASE2COMPLETEDMDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD
NCT05414708Not specifiedRECRUITINGArt Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms
NCT05900479Not specifiedACTIVE_NOT_RECRUITINGMulti-site, Longitudinal Trial Evaluating the Efficacy, Mechanisms, and Moderators of Service Dogs for Military Veterans With PTSD
NCT06723834Not specifiedENROLLING_BY_INVITATIONService Dogs and Prolonged Exposure Therapy for Military-Connected PTSD
NCT00285246Not specifiedCOMPLETEDProspective Study of Veteran Health in Previously Deployed Soldiers
NCT00371176Not specifiedCOMPLETEDA Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD
NCT00419029Not specifiedCOMPLETEDMotivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment
NCT00539279Not specifiedCOMPLETEDTreatment of Older Veterans With Chronic Posttraumatic Stress Disorder
NCT00870545Not specifiedCOMPLETEDReintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study
NCT00974402Not specifiedCOMPLETEDPsychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings
NCT00990106Not specifiedCOMPLETEDAugmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
NCT01007006Not specifiedWITHDRAWNTelepharmacy Robotic Medicine Delivery Unit TRMDU Assessment
NCT01049516Not specifiedCOMPLETEDProlonged Exposure for Post Traumatic Stress Disorder (PTSD) Among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Personnel
NCT01062022Not specifiedTERMINATEDFOCUS-CI: A Preventive Intervention With Children and Families of the Combat Injured
NCT01330888Not specifiedCOMPLETEDExploring Deployment Stress and Reintegration in Army National Guard Chaplains
NCT01338506Not specifiedCOMPLETEDIntegrated Treatment of OEF/OIF Veterans With PTSD & Substance Use Disorders
NCT02226367Not specifiedCOMPLETEDPrazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD
NCT02556645Not specifiedCOMPLETEDA Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy (PCT) for PTSD Among Active-Duty Military Personnel
NCT02720497Not specifiedCOMPLETEDThe Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD
NCT02825602Not specifiedUNKNOWNVietnam Era Health Retrospective Observational Study
NCT03337750Not specifiedCOMPLETEDAn Open-Trial of Web-Prolonged Exposure (Web-PE) Among Active-Duty Military
NCT03736356Not specifiedTERMINATEDLong-term Health Outcomes of AE Casualties
NCT03795987Not specifiedCOMPLETEDTraumatic Nightmares Treated by NightWare (To Arouse Not Awaken)
NCT03828656Not specifiedUNKNOWNNightWare Open Enrollment Study
NCT03934658Not specifiedCOMPLETEDRemote Study of NightWare for PTSD With Nightmares
NCT03995992Not specifiedUNKNOWNBenefits of Diving Training on Recovery for Veterans Suffering of Chronic PTSD: an Exploratory Study
NCT04040387Not specifiedCOMPLETEDNightWare Randomized Trial 02
NCT04776304Not specifiedCOMPLETEDArt Therapy QEEG Study for Service Members with a Traumatic Brain Injury and Posttraumatic Stress Symptoms

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PRAZOSIN HYDROCHLORIDE43
CYCLOSERINE41
OMEGA-3-ACID ETHYL ESTERS41
QUETIAPINE41
MIDOMAFETAMINE31
LEVCYCLOSERINE21
CHEMBL454703201